ATS 2020 Advance Program

Objectives At the conclusion of this session, the participant will be able to: • learn new findings about the Phase III data of Elexacaftor/Tezacaftor/Ivacaftor (triple combination) for F508del homozygous and F508del heterozygous with minimal function mutations; • learn and understand the microbial environment of the CF airway through novel detection methods; • manage chronic respiratory infections in cystic fibrosis, including Pseudomonas aeruginosa, Staphyloccous aureus, filamentous fungi, and multidrug-resistant bacteria/mycobacteria. Highly-effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators improve lung function and reduce acute pulmonary exacerbations of cystic fibrosis (CF) lung disease. However, the battle against infections responsible for CF lung disease progression remains. This session will highlight and discuss the current research examining the microbial environment and emerging pathogens of the CF airway, management of chronic Pseudomonas aeruginosa colonization, role of anti-staphylococcal prophylaxis, and novel therapies for multi-drug resistant organisms in CF. Chairing: J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO G. Hong, MD, MHS, Philadelphia, PA A.R. Smyth, MD, Nottingham, United Kingdom 9:15 Introduction: The Landscape of Cystic Fibrosis with Highly-Effective CFTR Modulator Therapy J.L. Taylor-Cousar, MD, MSc, ATSF, Denver, CO 9:30 A Patient’s Perspective Speaker To Be Announced 9:35 Microbiota in the CF Airway Across the Disease Spectrum L. Caverly, BA, MD, Ann Arbor, MI 9:55 Fungus Among Us: Understanding the Role and Treatment of Fungi in the CFTRModulator Era G. Hong, MD, MHS, Philadelphia, PA 10:15 The Role of Anti-Staphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis A.R. Smyth, MD, Nottingham, United Kingdom 10:35 Azithromycin-Tobramycin Interaction Against Pseudomonas Aeruginosa in CF D.P. Nichols, MD, Seattle, WA 10:55 Bacteriophage-Based Therapy for Multi-Drug Resistant Bacteria in CF J.L. Koff, MD, New Haven, CT CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE B3 FELLOWS CASE CONFERENCE Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Pulmonary Circulation; Pulmonary Infections and Tuberculosis; Thoracic Oncology; Training Committee 9:15 a.m. - 11:15 a.m. Target Audience Clinicians, nurses, fellows, residents, and researchers looking to broaden their clinical acumen to facilitate clinical and translational research. Objectives At the conclusion of this session, the participant will be able to: • recognize clinical, radiographic, and pathologic findings of rare diseases; • gain insight into clinical decision making skills demonstrated by master clinicians, radiologists and pathologists which will improve the quality of learners' practice and potentially improve quality of care for the learner's patients; • develop strategies to evaluate patients with common symptoms that include uncommon/rare diseases in the differential diagnosis when appropriate. In this session, six unknown cases will be presented by fellows to a panel of experts in a traditional Clinical Pathology Conference (CPC) format. The panel of clinician experts will discuss the key clinical elements ATS 2020 • Philadelphia, PA MONDAY • MAY 18 67